Furthermore, antibody-drug conjugates targeting Trop2 (TACSTD2), such as Sacituzumab govitecan, have shown therapeutic effects in triple-negative breast cancer 14, indicating that TACSTD2 is a promising therapeutic target. The gene discussed is TACSTD2; the disease is triple-negative breast carcinoma.